Q-omics provides the consensus-scored MIR4730 profile across patient tissues and cancer cell-line models. MIR4730 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR4730 is differentially expressed in 6, with the highest sampling consensus in READ. Additionally, MIR4730 RNA expression shows 14,196 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, READ, and UVM as cancer lineages where MIR4730 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4730 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4730 survival associations across molecular data types. MIR4730 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4730 RNA expression–survival associations across cancer types. High MIR4730 expression shows unfavorable associations in KIRC, but favorable associations in UCS, BRCA, BLCA, PAAD and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR4730 RNA expression.
This table summarizes MIR4730 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4730. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4730 shows lower tumor expression in READ, UCEC and LUSC and higher tumor expression in LUAD, STAD and LIHC. The READ box plot shows higher MIR4730 RNA expression in normal versus tumor tissue (log2 FC = −1.080, t-test p = .012).
This table shows molecular features associated with MIR4730 in patient tissues and cancer cell lines. In patient samples, MIR4730 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
